Endotoxin removal devices for the treatment of sepsis and septic shock


Davies B et al. – A substantial body of experimental and clinical evidence suggests that neutralising or removing lipopolysaccharide endotoxin would be an effective adjunctive approach to the management of Gram–negative sepsis. Polymyxins are a group of cyclic cationic polypeptide antibiotics. Although they have useful antimicrobial activity against Gram–negative bacteria, their clinical use has been limited because of toxicity. However, in addition to their antimicrobial property, polymyxins can bind to and neutralise endotoxin.

source: Lancet infectious disease

Model Organisms and Human Health


In this issue of Science, we highlight the impressive efforts to describe and analyze the genomes of the two organisms—the fly Drosophila melanogaster and the nematode worm Caenorhabditis elegans—that serve as the best models for understanding the biology of all animals, including humans. Hundreds of scientists have collaborated in these two major studies, which have moved us far beyond the complete descriptions of the DNA molecules that make up the fly and worm genomes published a little more than a decade ago, an accomplishment that seemed amazing then. As summarized in the Perspective on p. 1758, the new findings reveal essentially all of the tens of thousands of RNA and protein molecules that each of these organisms produces, as well as how their genetic information is packaged. Extensive Web-based databases built on these data are freely available to everyone, greatly accelerating future discoveries. Strange as it may seem, this research, aimed at reaching a deep molecular understanding of how the bodies of a fly and a worm are formed and maintained, will be critical for improving human health.

source: science

Controversy in the Surgical Treatment of the Rheumatoid Hand


The clinical picture of rheumatoid arthritis (RA) is best viewed as a combination of systemic symptoms associated with the inflammatory process and articular symptoms related both to potentially reversible synovitis and structural damage brought on by inflammation. In simple terms, the treatment of inflammation is medical, and structural lesions often require surgical solutions. The prime indications for surgery in patients with RA are essentially determined by the patient and consist of a desire to obtain pain relief and/or functional improvement. Pain is difficult to quantify. Essential concepts regarding surgical intervention are that surgery is elective in all but a few rare situations and always requires local therapy. Any evaluation of surgical intervention must be based on its total effect on the patient. Although there have been immense advances in the surgical options for patients with rheumatoid arthritis over the last several decades, the role of specific procedures in the total picture has many areas of uncertainty and controversy.

source: science direct

A Supplement to Stop Seizures


Most people know how hard it can be to stick to a diet. But for children with epilepsy, maintaining a restrictive high-fat, low-carbohydrate regimen known as the ketogenic diet is far more difficult than any weight-loss plan. Someday, however, they may be able to control seizures with a simple supplement instead, if a new finding in mice holds up in humans.

Almost a third of epilepsy patients, many of them children, don’t respond to antiseizure drugs. For reasons that are not well understood, the ketogenic diet can prevent seizures for some of these children. But it’s by no means an easy fix. Patients need to eat 80% to 90% of their daily calories as fat, usually in the form of vegetable oil or butter. Only some versions of the diet allow any carbohydrates at all, and sugary desserts are off-limits. “Eating a cookie can break the effect of the diet, resulting in a seizure,” explains Karin Borges, a neurobiologist at the University of Queensland, Brisbane, in Australia.

Hoping to design a more palatable alternative to the ketogenic diet, Borges and her colleagues began experimenting with a synthetic oil often found in antiwrinkle creams and other cosmetics. The compound, called triheptanoin, is already used to treat certain metabolic disorders; researchers believe it works because it replenishes specific molecules needed to produce the energy-carrying molecule adenosine triphosphate (ATP). Borges reasoned that these metabolites, which are also the building blocks for certain chemical messengers in the brain, might be depleted by the flurry of brain activity that occurs during a seizure. Lower ATP levels in the brain can destabilize neurons, triggering more seizures. Borges hoped that a diet supplemented with triheptanoin would replenish the brain’s supply of metabolites and boost ATP production, helping to control epileptic bursts.

She and her colleagues tested this hypothesis in mice. Some of the rodents ate a normal laboratory diet, but others were fed a diet in which 35% of the calories came from triheptanoin. After 3 weeks, the researchers induced seizures in the mice using either a drug injection or electrical stimulation of the brain. It was more difficult to produce seizures in mice on the 35% triheptanoin diet, the team reports in this month’s issue of Neurobiology of Disease. The supplement had effects similar to those of some antiseizure drugs currently on the market, says Borges.

The team also found that triheptanoin restores some of the brain’s missing metabolites. But Borges cautions that there is a lot more research to do before her team knows for sure why the supplement acts as an anticonvulsant. The next step will be preparation for a clinical trial, she says, to see if what works for mice will be safe for people.

For humans, a diet composed of one-third triheptanoin adds up to almost 800 calories. Borges is hoping epilepsy patients won’t need quite such a high dose, however. If the compound works for them, she says, they should be able to resume a normal diet; they would just need to add the flavorless compound to their food, possibly by mixing it into sauces and salad dressings.

Targeting metabolites specifically, says Susan Masino, a neurobiologist at Trinity College in Hartford, Connecticut, “is a new concept in epilepsy therapy.” She believes that a dietary supplement like triheptanoin could make metabolic therapy more realistic for more people.

Adam Hartman, a pediatric neurologist at the Johns Hopkins University School of Medicine in Baltimore, Maryland, agrees. Borges’s research, he says, establishes that putting metabolites back into the brain is a viable technique for treating epilepsy. And, because triheptanoin has been used to treat humans in the past, the outlook for conducting a clinical trial is good.

source: science now

Familial Risks in Cancer of Unknown Primary: Tracking the Primary Sites


Cancer of unknown primary (CUP) is diagnosed at the metastatic stage, and despite extensive diagnostic work-up, the primary tumor often remains unidentified. No data are available on familial clustering of CUP. We hypothesize that familial clustering of CUP with other cancers may be informative of the primary sites.

Patients and Methods A total of 35,168 patients with CUP were identified in the Swedish Family-Cancer Database, and risks between family members were calculated for concordant (CUP-CUP) and discordant (CUP-any other cancer) cancers using standardized incidence ratio (SIR).

Results Familial cases of CUP accounted for 2.8% of all CUP cases in the offspring generation. Familial SIR for CUP was 1.69 when a sibling was diagnosed with CUP. As to discordant associations between siblings, CUP was associated with lung (SIR, 1.87), kidney (SIR, 1.82), liver (SIR, 1.67), ovarian (SIR, 1.45), colorectal (SIR, 1.26), and breast (SIR, 1.15) cancers and melanoma (SIR, 1.26). Upper aerodigestive tract, bladder, pancreatic, and prostate cancers were additionally associated with CUP. Notably, CUP was associated with families of kidney, lung, and colorectal cancers.

Conclusion The present data show that CUP is not a disease of random metastatic cancers but, instead, a disease of a defined set of cancers. The association of CUP with families of kidney, lung, and colorectal cancers suggests a marked genetic basis and shared metastatic mechanisms by many cancer types. Familial sites shared by CUP generally match those arising in tissue-of-origin determinations and, hence, suggest sites of origin for CUP. Mechanistic exploration of CUP may provide insight into defense against primary tumors and the metastatic process.

source:Journal of clinical oncology

Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.


Eye disease due to herpes simplex virus (HSV) commonly presents as epithelial keratitis.
OBJECTIVES: To compare the relative effectiveness of antiviral agents, interferon, and corneal debridement in the treatment of acute HSV epithelial keratitis.
SEARCH STRATEGY: We searched CENTRAL (The Cochrane Library 2010, Issue 4), MEDLINE (January 1950 to October 2010), EMBASE (January 1980 to October 2010), Latin American and Caribbean Literature on Health Sciences (LILACS) (January 1982 to October 2010), Zetoc (British Library`s Electronic Table of Contents), System for Information on Grey Literature in Europe (openSIGLE), Biosciences Information Service (BIOSIS), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov), Japan Information Center of Science and Technology (JICST-EPlus), and China Academic Journals database (CAJ) via China National Knowledge Infrastructure (CNKI) with citations confirmed using China/Asia On Demand (COAD). There were no language or date restrictions in the search for trials. All databases except CNKI and COAD were last searched on 27 October 2010, CNKI and COAD were searched on 1 April 2010. We also searched literature digests, conference proceedings and reference lists.
SELECTION CRITERIA: Of 152 eligible studies,106 comparative treatment trials involving 5872 eyes with dendritic or geographic epithelial keratitis were analysed for corneal healing over two weeks.
DATA COLLECTION AND ANALYSIS: Interventions were compared at 14 days after trial enrolment by calculating a risk ratio (RR) that was adjusted with indirect RR, assessed by an inconsistency index (I(2) ) and supplemented by a seven-day RR and a hazard ratio (HR).
MAIN RESULTS: Idoxuridine, though uncertainly better in healing outcome than control because of few trials with 14-day follow up, allowed earlier corneal re-epithelialisation. Vidarabine resulted in a significantly better outcome than placebo in one trial (RR 1.96; 95% CI 1.10 to 3.49). Compared to idoxuridine, in combined direct and indirect analyses, vidarabine (RR 1.11; 95% CI 1.03 to 1.19), trifluridine (RR 1.31; 95% CI 1.20 to 1.42), acyclovir (RR 1.23; 95% CI 1.16 to 1.31), brivudine (RR 1.38; 95% CI 1.18 to 1.61), and ganciclovir (RR 1.40; 95% CI 1.25 to 1.57) were significantly more effective. Trifluridine (RR 1.12; 95% CI 1.04 to 1.21) and acyclovir (RR 1.11; 95% CI 1.05 to 1.19) appeared more effective than vidarabine. No significant differences were found in comparisons between acyclovir, trifluridine and brivudine. The comparison of ganciclovir to acyclovir was limited by heterogeneity and possible publication bias. The joint use of two topical antivirals (RR 1.00; 95% CI 0.89 to 1.12) and the use of oral acyclovir alone (RR 0.92; 95% CI 0.79 to 1.07) or combined with a topical antiviral (RR 1.08; 95% CI 0.99 to 1.17) appeared as effective as topical antiviral therapy. Compared to antiviral monotherapy, the combination of an antiviral with interferon (RR 1.03; 95% CI 0.99 to 1.07) or with debridement (RR 1.04; 95% CI 0.95 to 1.14) did not yield significantly better outcomes but may have accelerated healing. The corneal epithelial healing outcome was improved when antiviral therapy was added to debridement (RR 1.21; 95% CI 1.04 to 1.42).
AUTHORS’ CONCLUSIONS: Trifluridine and acyclovir are more effective than idoxuridine or vidarabine, and similar in therapeutic effectiveness. Brivudine and ganciclovir are at least as effective as acyclovir. While not improving outcome, the combination of interferon and an antiviral agent may speed healing. The effectiveness of corneal epithelial debridement is improved by an antiviral agent.

Vitamin D and asthma


Mak G et al. – Asthma is a disease that continues to carry a significant health burden on humanity. Vitamin D is thought to play a role in many chronic diseases as it may possess immunomodulatory properties. Vitamin D has a complex role on the immune system and its regulation of various aspects of immunity has allowed speculation on its potential role in asthma. However, the net effect of vitamin D on the immune system and its role in asthma still remains unanswered. More research needs to address the diagnostic and therapeutic implications vitamin D may have in the future of asthma management.

source: current opinions in pulmonary medicine

Infectious moods: How bugs control your mind


Happiness is catching (Image: Jimmy Turnball)
The brain is supposed to be isolated from the immune system – but now it seems that happiness, depression and even mental illness really can be catching

FEELING happy? Down in the dumps? Or been behaving strangely lately? Besides the obvious reasons, whether or not you are happy or sad, or prone to depression or other mental illnesses, could be a consequence of an infection – or even down to the diseases that you didn’t catch during childhood.

“It used to be thought that the immune system and the nervous system were worlds apart,” says John Bienenstock of McMaster University in Hamilton, Canada. Now it seems the immune system, and infections that stimulate it, can influence our moods, memory and ability to learn. Some strange behaviours, such as obsessive compulsive disorder, may be triggered by infections, and the immune system may even shape our basic personalities, such as how anxious or impulsive we are. The good news is that understanding these links between the brain and immune system could lead to new ways of treating all kinds of disorders, from depression to Tourette’s syndrome.

This is a massive shift in thinking. Not so long ago, the blood-brain barrier was thought to isolate the brain from the immune system. The cells that make up the walls of blood capillaries are joined together more tightly in the brain than elsewhere in the body, preventing proteins and cells getting into the brain. Now, though, it is becoming clear that antibodies, signalling molecules and even immune cells often get through, sometimes with radical effects. In fact, immune cells do not even need to reach the brain to influence it. Here we look at some of the effects they can have.

source: new scientist

Pegylated Interferon-Lambda for Chronic Hepatitis C Virus Infection


In a phase Ib study, PEG-IFN-{lambda} showed promise in both treatment-naive and relapsing patients.

The cornerstone for treating patients with hepatitis C virus (HCV) infection is pegylated interferon alfa (PEG-IFN-{alpha}) plus ribavirin. However, adverse effects can reduce quality of life, lead to dose reductions, and even prompt discontinuation of therapy, with potential consequences for efficacy. Interferon-{lambda}1, also known as interleukin-29, has shown in vitro antiviral activity similar to that of PEG-IFN-{alpha}. Unlike the widely distributed IFN-{alpha} receptors, expression of the IFN-{lambda}1 receptor is more restricted, suggesting that a treatment that targets IFN-{lambda}1 might be less prone to cause adverse effects.

In an industry-funded, open-label phase-Ib study, investigators tested the efficacy of PEG-IFN-{lambda} in HCV genotype 1–infected patients. Twenty-four patients who had relapsed on PEG-IFN-{alpha} therapy received PEG-IFN-{lambda} monotherapy (1.5 µg/kg or 3.0 µg/kg, either weekly or twice weekly), 25 patients who had relapsed on IFN-{alpha} therapy received PEG-IFN-{lambda} (0.50–2.25 µg/kg weekly) plus ribavirin, and 7 treatment-naive patients received PEG-IFN-{lambda} (1.5 µg/kg weekly) plus ribavirin. All treatments lasted 4 weeks; antiviral and safety assessments were made for at least another 4 weeks.

In two of the seven treatment-naive patients, HCV became undetectable by week 4. All PEG-IFN-{lambda} doses induced virologic response, in a roughly dose-related pattern. Flu-like symptoms were uncommon; hematologic abnormalities were observed only in relation to use of ribavirin. The most commonly reported adverse symptoms were fatigue (29%), nausea (12%), and myalgias (11%). The incidence of adverse events was not dose related.

Comment: Current and future HCV therapies are likely to use interferon as the backbone. In this study, PEG-IFN-{lambda} had strong antiviral activity with minimal adverse effects. If later-phase trials confirm the virologic response and low incidence of adverse effects, PEG-IFN-{lambda} could become the foundation of future treatment regimens. Both treatment-naive and relapsing patients might then have treatment options that are more effective, better tolerated, and less likely to be discontinued than currently available therapies.

David A. Johnson, MD

Published in Journal Watch Gastroenterology December 22, 2010

GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study


Biomarker levels in blood after traumatic brain injury (TBI) may offer diagnostic and prognostic tools in addition to clinical indices. This study aims to validate glial fibrillary acidic protein (GFAP) and S100B concentrations in blood as outcome predictors of TBI using cutoff levels of 1.5 mug/L for GFAP and 1.13 mug/L for S100B from a previous study.
METHODS: In 79 patients with TBI (Glasgow Coma Scale score [GCS] </=12), serum, taken at hospital admission, was analyzed for GFAP and S100B. Data collected included injury mechanism, age, gender, mass lesion on CT, GCS, pupillary reactions, Injury Severity Score (ISS), presence of hypoxia, and hypotension. Outcome was assessed, using the Glasgow Outcome Scale Extended (dichotomized in death vs alive and unfavorable vs favorable), 6 months post injury.
RESULTS: In patients who died compared to alive patients, median serum levels were increased: GFAP 33.4-fold and S100B 2.1-fold. In unfavorable compared to favorable outcome, GFAP was increased 19.8-fold and S100B 2.1-fold. Univariate logistic regression analysis revealed that mass lesion, GFAP, absent pupils, age, and ISS, but not GCS, hypotension, or hypoxia, predicted death and unfavorable outcome. Multivariable analysis showed that models containing mass lesion, pupils, GFAP, and S100B were the strongest in predicting death and unfavorable outcome. S100B was the strongest single predictor of unfavorable outcome with 100% discrimination.
CONCLUSION: This study confirms that GFAP and S100B levels in serum are adjuncts to the assessment of brain damage after TBI and may enhance prognostication when combined with clinical variables.

source: neurology